Prot #PRT811-01: REFMAL 655: A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas

Project: Research project

Project Details

StatusActive
Effective start/end date4/7/22 → 4/7/25

Funding

  • SCRI Development Innovations, LLC (Prot #PRT811-01)
  • Prelude Therapeutics Inc (Prot #PRT811-01)